Biocon Reports Q1FY18 Revenue at Rs 988 Crore; EBITDA at Rs 246 Crore; Net Profit at Rs 81 Crore

  • Posted by: Biocon Biologics

FDA Oncologic Drugs Advisory Committee Unanimously Recommends Approval of Mylan and Biocon’s Proposed Biosimilar Trastuzumab

  • Posted by: Biocon Biologics

Biocon Receives GMP approval for Biologics Drug Substance facilities from French Regulator; Drug Product facility to be re-inspected

  • Posted by: Biocon Biologics

Mylan and Biocon Present Clinical Data on Insulin Glargine at the American Diabetes Association’s 77th Scientific Sessions

  • Posted by: Biocon Biologics

Biocon Appoints Ms. Pratima Rao as Mission Director of Biocon Foundation

  • Posted by: Biocon Biologics

Media Reports on USFDA 483s

  • Posted by: Biocon Biologics

Kiran Mazumdar Shaw Felicitated with ‘AWSM Award for Excellence 2017’ by The Feinstein Institute for Medical Research, USA

  • Posted by: Biocon Biologics

Biocon Q4 FY17 Revenue Rs 974 Cr; Net Profit Rs 127 Cr; FY17 Revenue at Rs 4,079 Cr; Net Profit at Rs 612 Cr

  • Posted by: Biocon Biologics

U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon’s Proposed Biosimilar Pegfilgrastim for Review

  • Posted by: Biocon Biologics

Biocon Foundation & Department of Medical, Health & Family Welfare, Govt. of Karnataka Collaborate to Set Up Smart eLAJ Clinics in Karnataka

  • Posted by: Biocon Biologics
Share